Use of [.sup.18]F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung

The purpose of the present prospective study was to evaluate the use of [.sup.18]F-fuorodeoxyglucose positron emission tomography/computed tomography ([.sup.18]F-FDG PET/CT) in the assessment of therapy response and the prediction of short-term outcomes by maximum and mean standardized uptake values...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-07, Vol.16 (1), p.1067
Main Authors: Zhao, Xiang-Rong, Zhang, Yong, Yu, Yong-Hua
Format: Article
Language:English
Subjects:
Care and treatment
Chemotherapy
Diagnosis
Lung cancer
Patient outcomes
Radiotherapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of the present prospective study was to evaluate the use of [.sup.18]F-fuorodeoxyglucose positron emission tomography/computed tomography ([.sup.18]F-FDG PET/CT) in the assessment of therapy response and the prediction of short-term outcomes by maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) following chemoradiotherapy (CRT) in patients with stage III adenocarcinoma of the lung. The study included a total of 15 patients, all of whom underwent two serial [.sup.18]F-FDG PET/CT scans prior to and following 60-Gy radiotherapy with a concurrent cisplatin/pemetrexed combined chemotherapy regimen. SUVmax, SUVmean, MTV and TLG were determined. Short-term outcomes were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) and the PET Response Criteria in Solid Tumors (PERCIST). Post-CRT SUVmax, [DELTA]SUVmax, [DELTA]MTV and [DELTA]TLG varied significantly between responders and non-responders (P=0.009, P=0.015, P=0.006 and P=0.004, respectively). The differences in SUVmax, SUVmean, carcinoembryonic antigen, MTV and TLG between the responders and the non-responders at the initial [.sup.18]F-FDG PET/CT scans were not statistically significant (P>0.05). The overall response rate was significantly higher (P=0.01) when evaluated using PERCIST compared with evaluation using RECIST. It was concluded that post-CRT SUVmax, [DELTA]SUVmax, [DELTA]MTV and [DELTA]TLG may be used to differentiate the responders from the non-responders following CRT for stage III adenocarcinoma of the lung. This would aid in deciding whether or not to increase dosages or to incorporate a boost treatment without the requirement to suspend therapy.
ISSN:1792-1074
DOI:10.3892/ol.2018.8748